Skip to main content

Table 2 In vitro susceptibilities of Gram-positive isolates obtained from the ATLAS program, 2018

From: In vitro activity of ceftaroline, ceftazidime-avibactam, and comparators against Gram-positive and -negative organisms in China: the 2018 results from the ATLAS program

Organism/Antibiotic

MIC50

MIC90

MIC Range

% Susceptible

% Intermediate

% Resistant

MRSA (n = 155)

Ceftaroline

1

2

≤ 0.06-2

83.9

16.1

0

Ampicillin

> 8

> 8

2->8

NA

NA

NA

Ampicillin-sulbactam

8/4

> 8/4

0.5/0.25->8/4

NA

NA

NA

Levofloxacin

0.25

> 4

0.06->4

71.0

0.6

28.4

Tigecycline

0.25

0.5

0.06-1

93.5

6.5

0

MSSA (n = 251)

Ceftaroline

0.5

0.5

0.12-1

100

0

0

Ampicillin

> 8

> 8

≤ 0.25->8

NA

NA

NA

Ampicillin-sulbactam

2/1

4/2

≤ 0.25/0.12->8/4

NA

NA

NA

Levofloxacin

0.25

> 4

0.06->4

88.4

0.8

10.8

Tigecycline

0.25

0.5

0.06-1

99.2

0.8

0

Enterococcus faecalis(n = 109)

Ceftaroline

2

4

0.12->16

NA

NA

NA

Ampicillin

1

2

≤ 0.25-2

100

0

0

Ampicillin-sulbactam

1/0.5

2/1

≤ 0.25/0.12-2/1

NA

NA

NA

Levofloxacin

1

> 4

0.25->4

73.4

0

26.6

Tigecycline

0.25

0.5

0.06–0.5

74.3

25.7

0

Enterococcus faecium(n = 64)

Ceftaroline

> 16

> 16

2->16

NA

NA

NA

Ampicillin

> 8

> 8

1->8

9.4

0

90.6

Ampicillin-sulbactam

> 8/4

> 8/4

1/0.5->8/4

NA

NA

NA

Levofloxacin

> 4

> 4

0.5->4

4.7

0

95.3

Tigecycline

0.12

0.25

0.03–0.25

NA

NA

NA

Streptococcus pneumoniae(n = 77)a

Ceftaroline

0.06

0.25

0.008-0.5

100

0

0

Penicillin

0.5

4

≤ 0.06->4

44.16

9.09

46.75

Ampicillin-sulbactam

0.5/0.25

> 4/2

≤ 0.12/0.06->4/2

NA

NA

NA

Cefoperazone-sulbactam

2/2

> 4/4

≤ 0.12/0.12->4/4

NA

NA

NA

Levofloxacin

1

1

0.5-2

100

0

0

Meropenem

0.12

1

≤ 0.03-1

55.8

23.4

20.8

Piperacillin-tazobactam

1/4

> 4/4

≤ 0.25/4->4/4

NA

NA

NA

Tigecycline

0.015

0.03

≤ 0.008–0.06

100

0

0

PRSP (n = 36)

Ceftaroline

0.25

0.25

0.06–0.5

100

0

0

Ampicillin-sulbactam

4/2

> 4/2

2/1->4/2

NA

NA

NA

Cefoperazone-sulbactam

4/4

> 4/4

2/2->4/4

NA

NA

NA

Levofloxacin

1

1

0.5-2

100

0

0

Meropenem

0.5

1

0.25-1

8.3

47.2

44.4

Piperacillin-tazobactam

> 4/4

> 4/4

2/4->4/4

NA

NA

NA

Tigecycline

0.015

0.03

0.015–0.03

100

0

0

PSSP (n = 34)b

Ceftaroline

0.015

0.03

0.008–0.12

100

0

0

Ampicillin-sulbactam

≤ 0.12/0.06

≤ 0.12/0.06

≤ 0.12/0.06-≤0.12/0.06

NA

NA

NA

Cefoperazone-sulbactam

≤ 0.12/0.12

0.25/0.25

≤ 0.12/0.12-1/1

NA

NA

NA

Levofloxacin

1

2

0.5-2

100

0

0

Meropenem

≤ 0.03

≤ 0.03

≤ 0.03–0.5

97.1

2.9

0

Piperacillin-tazobactam

≤ 0.25/4

≤ 0.25/4

≤ 0.25/4-≤0.25/4

NA

NA

NA

Tigecycline

0.015

0.03

≤ 0.008–0.06

100

0

0

Coagulase-negative staphylococci (n = 125)

Ceftaroline

0.5

4

≤ 0.06->16

NA

NA

NA

Ampicillin

> 8

> 8

≤ 0.25->8

NA

NA

NA

Ampicillin-sulbactam

4/2

> 8/4

≤ 0.25/0.12->8/4

NA

NA

NA

Levofloxacin

> 4

> 4

≤ 0.03->4

32.0

0.8

67.2

Tigecycline

0.25

0.5

0.03-1

NA

NA

NA

β-hemolytic streptococci (n = 64)c

Ceftaroline

0.015

0.03

≤ 0.004–0.06

100

0

0

Ampicillin-sulbactam

≤ 0.12/0.06

≤ 0.12/0.06

≤ 0.12/0.06–0.5/0.25

NA

NA

NA

Cefoperazone-sulbactam

0.25/0.25

1/1

≤ 0.12/0.12-4/4

NA

NA

NA

Levofloxacin

0.5

1

≤ 0.25->4

98.4

0

1.6

Meropenem

≤ 0.03

0.12

≤ 0.03–0.25

100

0

0

Piperacillin-tazobactam

≤ 0.25/4

0.5/4

≤ 0.25/4-0.5/4

NA

NA

NA

Tigecycline

0.03

0.06

≤ 0.008–0.12

100

0

0

  1. MIC = minimal inhibitory concentration; CLSI = Clinical and Laboratory Standards Institute; MRSA = methicillin-resistant Staphylococcus aureus; MSSA = methicillin-susceptible Staphylococcus aureus; PRSP = penicillin-resistant Streptococcus pneumoniae; PSSP = penicillin-susceptible Streptococcus pneumoniae; NA = not applicable
  2. a. For levofloxacin, 76 Streptococcus pneumoniae isolates were tested
  3. b. For levofloxacin, 33 penicillin-susceptible Streptococcus pneumoniae isolates were tested
  4. c. For levofloxacin, 63 β-hemolytic streptococci isolates were tested